Features | Partner Sites | Information | LinkXpress
Sign In
Ampronix
GLOBETECH PUBLISHING
Fluke Biomedical

Red Reflex Test Helps Rule Out Retinoblastoma

By HospiMedica International staff writers
Posted on 04 Jun 2014
Image: The CHECT Red Reflex Poster – link provided below (Photo courtesy of CHECT).
Image: The CHECT Red Reflex Poster – link provided below (Photo courtesy of CHECT).
General Practitioners (GPs) in the United Kingdom are being urged to ensure every squint is checked to rule out eye cancer.

The Childhood Eye Cancer Trust (CHECT; London, United Kingdom) is urging that all squints in babies and young children be checked with a red reflex test to exclude a diagnosis of retinoblastoma (Rb). As squints are common in babies up to the age of three months, the only way to determine whether this is a sign of a much more serious condition is to carry out the test, a noninvasive procedure that involves looking in the eye with a hand-held ophthalmoscope.

To promote this message, CHECT has developed e-cards and an email campaign that GPs can share and forward on to colleagues. The campaign asks that particular attention be paid to children with a recently onset squint; a white pupillary reflex (leukocoria); an abnormal reflex in photographs taken with a flash; a change in color of the iris; or a deterioration in vision. According to figures released by CHECT, 26% of babies and young children diagnosed with Rb presented with a squint, which is the second most common symptom of the disease (after leukocoria).

“In our experience, some babies and young children are facing serious delays in receiving life-saving treatment as a result of parents either being told incorrectly that their baby's squint is completely normal, or being given a non-urgent squint referral,” said Joy Felgate, CEO of CHECT. “If you are unable to confidently rule out retinoblastoma with a red reflex test, NICE guidelines state an urgent referral must be made to the local ophthalmology department stating 'suspected retinoblastoma.'”

Retinoblastoma is a fast-growing cancer that develops from the immature cells of a retina, affecting mainly children up to five years of age. Early detection of this aggressive condition is crucial to offer the child the best chance of saving their vision, their eyes, and their life. There are two forms of the disease, a heritable form and nonheritable form; about 55% of children with Rb have the nonheritable form. In about two thirds of cases, only one eye is affected (unilateral retinoblastoma); in the other third, tumors develop in both eyes.

Related Links:

Childhood Eye Cancer Trust
CHECT Red Reflex Poster



MinXray
Centurion Service
Bovie Medical

Channels

Surgical Techniques

view channel
Image: The Optimis Fusion integrated laser platform (Photo courtesy of Quantel Medical).

Combination Laser Platform Treats Glaucoma and Cataract

An integrated laser offers ophthalmologists a versatile armamentarium for treating both cataract and glaucoma in an efficient combination platform. The Optimis Fusion integrated laser combines advanced... Read more

Women's Health

view channel
Image: A prototype contraceptive implant (Photo courtesy of MicroCHIPS).

Contraceptive Implant Hails New Era of Birth Control

A fingernail-sized implant holds enough 30-microgram daily doses of levonorgestrel to provide contraception for 16 years. Developed by MicroCHIPS (Lexington, MA, USA), a MIT (Cambridge, MA, USA) startup,... Read more

Health IT

view channel

Wikipedia Dominates Internet Drug Information

Wikipedia, along with Google and WebMD, is where more than half of all Americans turn to for health information on prescription drugs. Researchers at the Blackstone Group (London, United Kingdom), Harvard Medical School (Boston, MA, USA), and other institutions selected new drug-safety communications related to prescription... Read more

Business

view channel

Spectranetics Completes Acquisition of AngioScore

Spectranetics (Colorado Springs, CO, USA) has completed the acquisition of AngioScore (Fremont, CA, USA), a leading developer, manufacturer, and marketer of cardiovascular specialty balloons. The transaction, for USD 230 million in cash and contingent commercial and regulatory milestone payments, will combine differentiated,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.